Sterpetti P, Hack A A, Bashar M P, Park B, Cheng S D, Knoll J H, Urano T, Feig L A, Toksoz D
Department of Physiology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Mol Cell Biol. 1999 Feb;19(2):1334-45. doi: 10.1128/MCB.19.2.1334.
The human lbc oncogene product is a guanine nucleotide exchange factor that specifically activates the Rho small GTP binding protein, thus resulting in biologically active, GTP-bound Rho, which in turn mediates actin cytoskeletal reorganization, gene transcription, and entry into the mitotic S phase. In order to elucidate the mechanism of onco-Lbc transformation, here we report that while proto- and onco-lbc cDNAs encode identical N-terminal dbl oncogene homology (DH) and pleckstrin homology (PH) domains, proto-Lbc encodes a novel C terminus absent in the oncoprotein that includes a predicted alpha-helical region homologous to cyto-matrix proteins, followed by a proline-rich region. The lbc proto-oncogene maps to chromosome 15, and onco-lbc represents a fusion of the lbc proto-oncogene N terminus with a short, unrelated C-terminal sequence from chromosome 7. Both onco- and proto-Lbc can promote formation of GTP-bound Rho in vivo. Proto-Lbc transforming activity is much reduced compared to that of onco-Lbc, and a significant increase in transforming activity requires truncation of both the alpha-helical and proline-rich regions in the proto-Lbc C terminus. Deletion of the chromosome 7-derived C terminus of onco-Lbc does not destroy transforming activity, demonstrating that it is loss of the proto-Lbc C terminus, rather than gain of an unrelated C-terminus by onco-Lbc, that confers transforming activity. Mutations of onco-Lbc DH and PH domains demonstrate that both domains are necessary for full transforming activity. The proto-Lbc product localizes to the particulate (membrane) fraction, while the majority of the onco-Lbc product is cytosolic, and mutations of the PH domain do not affect this localization. The proto-Lbc C-terminus alone localizes predominantly to the particulate fraction, indicating that the C terminus may play a major role in the correct subcellular localization of proto-Lbc, thus providing a mechanism for regulating Lbc oncogenic potential.
人类lbc癌基因产物是一种鸟嘌呤核苷酸交换因子,它特异性激活Rho小GTP结合蛋白,从而产生具有生物活性的、结合GTP的Rho,进而介导肌动蛋白细胞骨架重组、基因转录以及进入有丝分裂S期。为了阐明癌基因Lbc的转化机制,我们在此报告,虽然原癌基因和癌基因lbc的cDNA编码相同的N端dbl癌基因同源(DH)结构域和普列克底物蛋白同源(PH)结构域,但原癌基因Lbc编码一种癌蛋白中不存在的新型C末端,该末端包括一个与细胞基质蛋白同源的预测α螺旋区域,随后是一个富含脯氨酸的区域。lbc原癌基因定位于15号染色体,癌基因Lbc代表lbc原癌基因N末端与来自7号染色体的短的、不相关的C末端序列的融合。癌基因Lbc和原癌基因Lbc在体内均可促进结合GTP的Rho的形成。与癌基因Lbc相比,原癌基因Lbc的转化活性大大降低,转化活性的显著增加需要截断原癌基因Lbc C末端的α螺旋区域和富含脯氨酸的区域。删除癌基因Lbc的7号染色体衍生的C末端不会破坏转化活性,这表明赋予转化活性的是原癌基因Lbc C末端的缺失,而不是癌基因Lbc获得了不相关的C末端。癌基因Lbc的DH和PH结构域的突变表明,这两个结构域对于完全转化活性都是必需的。原癌基因Lbc产物定位于颗粒(膜)部分,而大多数癌基因Lbc产物位于细胞质中,PH结构域的突变不影响这种定位。单独的原癌基因Lbc C末端主要定位于颗粒部分,表明C末端可能在原癌基因Lbc的正确亚细胞定位中起主要作用,从而为调节Lbc致癌潜能提供了一种机制。